Amedisys (AMED) Reaches $48.04 After 3.00% Down Move; Ophthotech Has 0.55 Sentiment

October 30, 2017 - By Michael Collier

The stock of Amedisys Inc (NASDAQ:AMED) is a huge mover today! The stock decreased 4.44% or $2.23 during the last trading session, reaching $48.04. About 316,188 shares traded. Amedisys Inc (NASDAQ:AMED) has risen 15.02% since October 30, 2016 and is uptrending. It has underperformed by 1.68% the S&P500.The move comes after 7 months negative chart setup for the $1.63 billion company. It was reported on Oct, 30 by Barchart.com. We have $46.60 PT which if reached, will make NASDAQ:AMED worth $48.90M less.

Ophthotech Corporation is a biopharmaceutical company. The company has market cap of $84.83 million. The Firm is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. It currently has negative earnings. The Company’s primary focus is developing therapeutics for age-related macular degeneration , which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Since May 8, 2017, it had 1 insider buy, and 4 insider sales for $4.35 million activity. PERKINS BRUCE D had bought 500 shares worth $29,845. $600,000 worth of Amedisys Inc (NASDAQ:AMED) shares were sold by NETTERVILLE JAKE L. Hall Linda J. sold $300,800 worth of stock or 5,000 shares. $1.40 million worth of Amedisys Inc (NASDAQ:AMED) shares were sold by Ginn Scott G. Pernosky Lawrence R also sold $2.09M worth of Amedisys Inc (NASDAQ:AMED) shares.

Analysts await Amedisys Inc (NASDAQ:AMED) to report earnings on November, 2. They expect $0.53 earnings per share, up 47.22% or $0.17 from last year’s $0.36 per share. AMED’s profit will be $17.98 million for 22.66 P/E if the $0.53 EPS becomes a reality. After $0.62 actual earnings per share reported by Amedisys Inc for the previous quarter, Wall Street now forecasts -14.52% negative EPS growth.

Investors sentiment increased to 1.75 in Q2 2017. Its up 0.69, from 1.06 in 2017Q1. It improved, as 9 investors sold Amedisys Inc shares while 42 reduced holdings. 32 funds opened positions while 57 raised stakes. 30.18 million shares or 2.20% less from 30.86 million shares in 2017Q1 were reported. Tiaa Cref Invest Ltd accumulated 0.01% or 128,135 shares. 1,000 were reported by Creative Planning. Sivik Glob Healthcare Ltd Liability Com holds 1.03% or 44,607 shares in its portfolio. Louisiana State Employees Retirement System holds 0.04% of its portfolio in Amedisys Inc (NASDAQ:AMED) for 11,400 shares. Principal Fin Group Inc Inc invested in 231,688 shares or 0.01% of the stock. Teachers Retirement Systems Of The State Of Kentucky holds 0.01% or 11,167 shares in its portfolio. Boston Advsr Limited Liability Company has invested 0.06% in Amedisys Inc (NASDAQ:AMED). Renaissance Techs Limited Co stated it has 28,618 shares. First Midwest Financial Bank Division has 0.27% invested in Amedisys Inc (NASDAQ:AMED) for 34,791 shares. Peak6 Invs L P has 0% invested in Amedisys Inc (NASDAQ:AMED). Royal National Bank & Trust Of Canada has invested 0% in Amedisys Inc (NASDAQ:AMED). Schwab Charles Invest Mgmt accumulated 162,531 shares. Credit Suisse Ag invested in 0% or 70,910 shares. Ubs Asset Mngmt Americas reported 14,572 shares. Commonwealth Equity Inc accumulated 4,139 shares.

Among 14 analysts covering Amedisys Inc. (NASDAQ:AMED), 5 have Buy rating, 0 Sell and 9 Hold. Therefore 36% are positive. Amedisys Inc. had 28 analyst reports since September 1, 2015 according to SRatingsIntel. On Monday, August 14 the stock rating was maintained by RBC Capital Markets with “Hold”. The rating was maintained by RBC Capital Markets on Monday, July 10 with “Hold”. The stock has “Outperform” rating by Wells Fargo on Tuesday, September 1. The firm has “Buy” rating given on Monday, November 7 by Mizuho. RBC Capital Markets maintained the stock with “Hold” rating in Monday, June 5 report. Jefferies maintained the stock with “Buy” rating in Wednesday, July 19 report. Benchmark initiated it with “Hold” rating and $50 target in Friday, January 27 report. Oppenheimer upgraded the shares of AMED in report on Monday, February 8 to “Outperform” rating. Mizuho upgraded it to “Buy” rating and $49.0 target in Tuesday, January 19 report. Mizuho maintained Amedisys Inc (NASDAQ:AMED) rating on Wednesday, March 1. Mizuho has “Neutral” rating and $50 target.

Amedisys, Inc. is a healthcare services company. The company has market cap of $1.63 billion. The Company’s divisions are Home Health, Hospice, Personal Care and Other. It has a 40.87 P/E ratio. The Firm is a well-known provider of home health, hospice and personal care services.

Analysts await Ophthotech Corp (NASDAQ:OPHT) to report earnings on November, 14. They expect $4.31 earnings per share, up 352.05% or $6.02 from last year’s $-1.71 per share. OPHT’s profit will be $154.92M for 0.14 P/E if the $4.31 EPS becomes a reality. After $-0.62 actual earnings per share reported by Ophthotech Corp for the previous quarter, Wall Street now forecasts -795.16% EPS growth.

Ratings analysis reveals 0 of Ophthotech’s analysts are positive. Out of 6 Wall Street analysts rating Ophthotech, 0 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. OPHT was included in 6 notes of analysts from December 12, 2016. JP Morgan downgraded the shares of OPHT in report on Monday, December 12 to “Neutral” rating. The rating was downgraded by Chardan Capital Markets to “Neutral” on Monday, December 12. The rating was upgraded by Goldman Sachs to “Neutral” on Tuesday, December 13. The stock of Ophthotech Corp (NASDAQ:OPHT) earned “Mkt Perform” rating by Leerink Swann on Monday, December 12. The stock has “Hold” rating by Gabelli on Tuesday, December 13. On Monday, December 12 the stock rating was downgraded by Citigroup to “Neutral”.

The stock increased 2.16% or $0.05 during the last trading session, reaching $2.36. About 434,532 shares traded. Ophthotech Corp (OPHT) has declined 94.82% since October 30, 2016 and is downtrending. It has underperformed by 111.52% the S&P500.

Armistice Capital Llc holds 0.78% of its portfolio in Ophthotech Corp for 2.40 million shares. Nine Chapters Capital Management Llc owns 11,300 shares or 0.27% of their US portfolio. Moreover, Bogle Investment Management L P De has 0.13% invested in the company for 710,284 shares. The New York-based Element Capital Management Llc has invested 0.08% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 172,157 shares.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $1,764 activity.